Hosted on MSN12h
HC Wainwright & Co. Initiates Coverage of CRISPR Therapeutics (CRSP) with Buy Recommendation
Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...
STAT16h
Pfizer’s Braftovi extends survival in colorectal cancer
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
STAT16h
FDA approves first xenotransplantation clinical trial, as United Therapeutics forges ahead
United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...
Crispr Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...